Clinical Trial Update: Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of Delanzomib in combination with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Delanzomib (delanzomib)
• Lenalidomide (lenalidomide)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-06-28